Within the large groups of the tumour panel, the highest incidences of MAGE-A1 expression were observed in bladder carcinoma (40%), lung carcinoma (32%), malignant melanoma (21%) and breast carcinoma (11%). This evidence concerns the gene MAGEA1 and urinary bladder carcinoma.